Xencor Appoints Allen Yang as Senior Vice President and Chief Medical Officer
December 18, 2019 at 08:01 am EST
Share
Xencor, Inc. announced the appointment of Allen Yang, M.D., Ph.D., as senior vice president and chief medical officer. He will be responsible for leading clinical development strategy and overseeing clinical operations for Xencor’s portfolio of XmAb® antibody drug candidates, including bispecific antibodies and cytokines. Dr. Yang joins Xencor from Jazz Pharmaceuticals, where he served as senior vice president, head of clinical development and acting chief medical officer. Before assuming his most recent role at Jazz, Dr. Yang was the therapeutic area head for hematology and oncology, assembling its clinical development team and overseeing several oncology products, including Erwinaze®, Defitelio® and Vyxeos®.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.